OKYO
OKYO Pharma Limited
Biotechnology
Market Cap$66M
5Y Perf.-21.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
OKYO vs LNTH
Revenue, margins, valuation, and 5-year total return — side by side.
LNTH
Lantheus Holdings, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$5.92B
5Y Perf.+32.8%
OKYO vs LNTH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OKYO | LNTH |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $66M | $5.92B |
| Revenue (TTM) | $0.00 | $1.55B |
| Net Income (TTM) | $-5M | $279M |
| Gross Margin | — | 60.5% |
| Operating Margin | — | 18.8% |
| Forward P/E | — | 17.5x |
| Total Debt | $0.00 | $738K |
| Cash & Equiv. | $2M | $359M |
OKYO vs LNTH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OKYO
LNTH
| Stock | May 22 | May 26 | Return |
|---|---|---|---|
| OKYO Pharma Limited (OKYO) | 100 | 79.0 | -21.0% |
| Lantheus Holdings, … (LNTH) | 100 | 132.8 | +32.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OKYO vs LNTH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LNTH leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
OKYO
OKYO Pharma Limited
The Income Pick
OKYO is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.79
- EPS growth 0.1%
Best for: income & stability and growth exposure
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder
LNTH carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 41.9% 10Y total return vs OKYO's -55.2%
- Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
- Beta 0.47, current ratio 2.70x
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LNTH | 0.5% revenue growth vs OKYO's -11K% |
| Quality / Margins | LNTH | 18.0% margin vs OKYO's -23.9% |
| Stability / Safety | LNTH | Beta 0.47 vs OKYO's 0.79 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | LNTH | +13.1% vs OKYO's +10.2% |
| Efficiency (ROA) | LNTH | 12.4% ROA vs OKYO's -128.4% |
OKYO vs LNTH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
OKYO vs LNTH — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOKYOLAGGINGLNTH
LNTHLantheus Holdings, In…
3leads
OKYOOKYO Pharma Limited
3leads
6 Total Categories
CATEGORYLEADERvs LNTHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
OKYO1/1
Valuation MetricsMultiples, price ratios, and targets
OKYO1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LNTH4/5
Total Returns1Y, 3Y, 5Y total returns with dividends
LNTH6/6
Risk & VolatilityBeta, volatility, and downside exposure
LNTH2/2
Analyst OutlookRatings, price targets, and dividends
OKYO1/1
Income & Cash Flow (Last 12 Months)
OKYO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
LNTH and OKYO operate at a comparable scale, with $1.5B and $0 in trailing revenue.
| Metric | OKYOOKYO Pharma Limit… | LNTHLantheus Holdings… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $1.5B |
| EBITDAEarnings before interest/tax | -$4M | $347M |
| Net IncomeAfter-tax profit | -$5M | $279M |
| Free Cash FlowCash after capex | -$2M | $372M |
| Gross MarginGross profit ÷ Revenue | — | +60.5% |
| Operating MarginEBIT ÷ Revenue | — | +18.8% |
| Net MarginNet income ÷ Revenue | — | +18.0% |
| FCF MarginFCF ÷ Revenue | — | +24.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +83.3% | +76.5% |
OKYO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
OKYO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | OKYOOKYO Pharma Limit… | LNTHLantheus Holdings… |
|---|---|---|
| Market CapShares × price | $66M | $5.9B |
| Enterprise ValueMkt cap + debt − cash | $64M | $5.6B |
| Trailing P/EPrice ÷ TTM EPS | -13.50x | 26.69x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.52x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 14.61x |
| Price / SalesMarket cap ÷ Revenue | — | 3.84x |
| Price / BookPrice ÷ Book value/share | — | 5.72x |
| Price / FCFMarket cap ÷ FCF | — | 16.73x |
OKYO leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
LNTH leads this category, winning 4 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), LNTH scores 5/9 vs OKYO's 3/9, reflecting solid financial health.
| Metric | OKYOOKYO Pharma Limit… | LNTHLantheus Holdings… |
|---|---|---|
| ROE (TTM)Return on equity | — | +24.3% |
| ROA (TTM)Return on assets | -128.4% | +12.4% |
| ROICReturn on invested capital | — | +30.6% |
| ROCEReturn on capital employed | — | +17.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | — | 0.00x |
| Net DebtTotal debt minus cash | -$2M | -$358M |
| Cash & Equiv.Liquid assets | $2M | $359M |
| Total DebtShort + long-term debt | $0 | $738,000 |
| Interest CoverageEBIT ÷ Interest expense | -8.03x | 11.72x |
LNTH leads this category, winning 4 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
LNTH leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $4,475 for OKYO. Over the past 12 months, LNTH leads with a +13.1% total return vs OKYO's +10.2%. The 3-year compound annual growth rate (CAGR) favors LNTH at -1.4% vs OKYO's -8.7% — a key indicator of consistent wealth creation.
| Metric | OKYOOKYO Pharma Limit… | LNTHLantheus Holdings… |
|---|---|---|
| YTD ReturnYear-to-date | -27.4% | +35.3% |
| 1-Year ReturnPast 12 months | +10.2% | +13.1% |
| 3-Year ReturnCumulative with dividends | -23.9% | -4.0% |
| 5-Year ReturnCumulative with dividends | -55.2% | +314.2% |
| 10-Year ReturnCumulative with dividends | -55.2% | +4192.5% |
| CAGR (3Y)Annualised 3-year return | -8.7% | -1.4% |
LNTH leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
LNTH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LNTH is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than OKYO's 0.79 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs OKYO's 48.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OKYOOKYO Pharma Limit… | LNTHLantheus Holdings… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 0.47x |
| 52-Week HighHighest price in past year | $3.35 | $93.00 |
| 52-Week LowLowest price in past year | $1.32 | $47.25 |
| % of 52W HighCurrent price vs 52-week peak | +48.4% | +97.8% |
| RSI (14)Momentum oscillator 0–100 | 54.9 | 61.2 |
| Avg Volume (50D)Average daily shares traded | 93K | 886K |
LNTH leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
OKYO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
| Metric | OKYOOKYO Pharma Limit… | LNTHLantheus Holdings… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $101.00 |
| # AnalystsCovering analysts | — | 17 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +5.1% |
OKYO leads this category, winning 1 of 1 comparable metric.
Key Takeaway
OKYO leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). LNTH leads in 3 (Profitability & Efficiency, Total Returns).
Best OverallOKYO Pharma Limited (OKYO)Leads 3 of 6 categories
Loading custom metrics...
OKYO vs LNTH: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is OKYO or LNTH a better buy right now?
Lantheus Holdings, Inc.
(LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OKYO or LNTH?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +314. 2%, compared to -55. 2% for OKYO Pharma Limited (OKYO). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus OKYO's -55. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OKYO or LNTH?
By beta (market sensitivity over 5 years), Lantheus Holdings, Inc.
(LNTH) is the lower-risk stock at 0. 47β versus OKYO Pharma Limited's 0. 79β — meaning OKYO is approximately 69% more volatile than LNTH relative to the S&P 500.
04Which has better profit margins — OKYO or LNTH?
Lantheus Holdings, Inc.
(LNTH) is the more profitable company, earning 15. 2% net margin versus 0. 0% for OKYO Pharma Limited — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LNTH leads at 20. 2% versus 0. 0% for OKYO. At the gross margin level — before operating expenses — LNTH leads at 61. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — OKYO or LNTH?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is OKYO or LNTH better for a retirement portfolio?
For long-horizon retirement investors, Lantheus Holdings, Inc.
(LNTH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 47)). Both have compounded well over 10 years (LNTH: +41. 9%, OKYO: -55. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between OKYO and LNTH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.